Interim Results of an Open-Label Study to Assess Humoral Immune Response to COVID-19 mRNA Vaccine in Participants with Relapsing Multiple Sclerosis Treated with Ofatumumab

A. H. Cross,A. Chinea, B. Hendin, M. J. Tullman, R. Aburashed,J. Stankiewicz, E. Lucassen,X. Meng, A. Bar-Or

MULTIPLE SCLEROSIS JOURNAL（2022）

Cited 1|Views7

No score

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined